Intellia Therapeutics, Inc. (NTLA) PT Raised to $28.00

Intellia Therapeutics, Inc. (NASDAQ:NTLA) had its price target boosted by Credit Suisse Group from $24.00 to $28.00 in a report released on Friday, November 3rd. The firm currently has an outperform rating on the stock.

Several other brokerages have also recently issued reports on NTLA. Jefferies Group LLC set a $42.00 target price on shares of Intellia Therapeutics and gave the stock a buy rating in a report on Tuesday, October 31st. Zacks Investment Research raised Intellia Therapeutics from a sell rating to a hold rating in a research note on Wednesday, October 4th. Leerink Swann raised their price target on Intellia Therapeutics from $29.00 to $37.00 and gave the stock an outperform rating in a research note on Tuesday, October 31st. They noted that the move was a valuation call. Wedbush reissued an ourperform rating and set a $25.00 price objective (down previously from $29.00) on shares of Intellia Therapeutics in a research report on Wednesday, September 27th. Finally, ValuEngine raised Intellia Therapeutics from a sell rating to a hold rating in a research report on Friday, September 22nd. One analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. The company currently has an average rating of Hold and a consensus target price of $30.17.

Shares of Intellia Therapeutics (NASDAQ:NTLA) traded up $1.90 during midday trading on Friday, reaching $22.56. 863,708 shares of the company’s stock were exchanged, compared to its average volume of 329,652. Intellia Therapeutics has a twelve month low of $10.83 and a twelve month high of $33.34.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Tuesday, October 31st. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.06. Intellia Therapeutics had a negative net margin of 215.92% and a negative return on equity of 28.01%. The business had revenue of $7.30 million for the quarter, compared to analysts’ expectations of $5.83 million. During the same period last year, the business earned ($0.22) earnings per share. The business’s quarterly revenue was up 49.0% on a year-over-year basis. equities research analysts predict that Intellia Therapeutics will post -1.68 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Intellia Therapeutics, Inc. (NTLA) PT Raised to $28.00” was originally published by BBNS and is the property of of BBNS. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://baseballnewssource.com/markets/intellia-therapeutics-inc-ntla-pt-raised-to-28-00/1756682.html.

Several institutional investors have recently added to or reduced their stakes in NTLA. GMT Capital Corp bought a new stake in shares of Intellia Therapeutics during the 3rd quarter valued at about $8,214,000. Ark Investment Management LLC lifted its position in shares of Intellia Therapeutics by 118.9% during the 2nd quarter. Ark Investment Management LLC now owns 174,810 shares of the company’s stock valued at $2,797,000 after buying an additional 94,960 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Intellia Therapeutics by 10.2% during the 2nd quarter. Vanguard Group Inc. now owns 997,288 shares of the company’s stock valued at $15,957,000 after buying an additional 92,580 shares in the last quarter. OxFORD Asset Management LLP purchased a new position in shares of Intellia Therapeutics during the 2nd quarter valued at about $1,132,000. Finally, GSA Capital Partners LLP purchased a new position in shares of Intellia Therapeutics during the 2nd quarter valued at about $907,000. Institutional investors and hedge funds own 48.89% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees
Free Agency Season Has Finally Heated Up
Free Agency Season Has Finally Heated Up


Leave a Reply

 
© 2006-2017 BBNS.